| Old | New | Differences | |
|---|---|---|---|
| 1 | 1 | ||
| 2 | 2 | ||
| 3 | 3 | LCO No. 937 1 of 1 | |
| 4 | 4 | ||
| 5 | 5 | General Assembly Proposed Bill No. 27 | |
| 6 | 6 | January Session, 2019 | |
| 7 | 7 | LCO No. 937 | |
| 8 | 8 | ||
| 9 | 9 | ||
| 10 | 10 | Referred to Committee on HUMAN SERVICES | |
| 11 | 11 | ||
| 12 | 12 | ||
| 13 | 13 | Introduced by: | |
| 14 | 14 | SEN. LOONEY, 11th Dist. | |
| 15 | 15 | ||
| 16 | 16 | ||
| 17 | 17 | ||
| 18 | 18 | AN ACT REDUCING PRESCRIPTION DRUG PRICES UNDER THE | |
| 19 | 19 | MEDICAID PROGRAM. | |
| 20 | 20 | Be it enacted by the Senate and House of Representatives in General | |
| 21 | 21 | Assembly convened: | |
| 22 | 22 | ||
| 23 | 23 | That chapter 319v of the general statutes be amended to authorize 1 | |
| 24 | 24 | the Commissioner of Social Services to reduce prescription drug costs 2 | |
| 25 | 25 | under the Medicaid program by establishing: (1) A price cap that 3 | |
| 26 | 26 | requires (A) additional negotiation for prescription drug rebates with 4 | |
| 27 | 27 | manufacturers and review by the board established pursuant to 5 | |
| 28 | 28 | section 17b-274d of the general statutes whenever the cap is exceeded, 6 | |
| 29 | 29 | and (B) further restrictions on prescription drug purchases and 7 | |
| 30 | 30 | transparency regarding actual prescription drug manufacturing costs 8 | |
| 31 | 31 | when negotiations fail, and (2) a transparent reimbursement model for 9 | |
| 32 | 32 | pharmaceutical benefit managers that allows the state Medicaid 10 | |
| 33 | 33 | program to pay the discounted cost for prescription drugs negotiated 11 | |
| 34 | 34 | by such managers. 12 | |
| 35 | 35 | Statement of Purpose: | |
| 36 | 36 | To lower health care costs under the Medicaid program. |